32 results about "Vaccine Stability" patented technology

The invention provides fusion protein and a nucleotide sequence thereof. The fusion protein comprises a toxoplasma P30 protein subunit and a T cell antigenic epitope. The invention further provides avaccine using the fusion protein to prevent abortion of pregnant sows due to toxoplasmosis and a vaccine composition thereof. The fusion protein has the beneficial effects of the characteristics of high expression quantity and high immunogenicity. The vaccine and the vaccine composition can effectively prevent abortion of the pregnant sows due to the toxoplasmosis and are high in vaccine stability.

The invention relates to a heatproof freeze-drying protecting agent for recombined pseudorabies virus vaccines. The heatproof freeze-drying protecting agent comprises, by weight, 4-8% of trehalose, 0-3% of cane sugar, 0.2-0.8% of sorbitol, 1-3% of polyvinylpyrrolidone K-30, 4-7% of soybean protein isolate, 0.5-1% of wheat proteolysis product and the balance injection water. The invention further provides a preparation method of the heatproof freeze-drying protecting agent for the recombined pseudorabies virus vaccines. The heatproof freeze-drying protecting agent is simple in formula, easy to prepare and suitable for mass production, has the advantages of high vaccine stability, prolonged vaccine shelf life and the like, and does not contain gelatin and animal source ingredients. Safety of the vaccines is high when the protecting agent is applied to the vaccines.

The invention belongs to the field of biomedicine, and particularly relates to an application of MG132 as a vaccine production synergist and a stabilizing agent. The MG132 can increase the expressionlevel of ribonucleic acid virus structural protein VP3, further promotes the assembly of virus-like particles, and can be applied to virus-like particle expression synergists, virus-like particle production synergists and the stabilizing agents of related vaccines to promote vaccine production and improve vaccine stability.

The invention provides a method for preparing a serum-free cultured suspension mammal cell line, which comprises the following steps: 1)recovering and culturing mammal cells to obtain adherent cultured mammal cells, digesting by pancreatin; 2)culturing the adherent cultured mammal cells by a serum-free medium added with a certain amount of serum, continuously culturing the mammal cells so as to adapt to the serum-free medium with the certain amount of serum; and 3)repeating the continuous cultivation process in the step 2), and gradually reducing the serum addition amount in the serum-free medium until the serum addition in the serum-free medium is 0 to obtain the suspension mammal cell line. According to the method, equalization nutrition of cells is obtained, vaccine stability and uniformity can be guaranteed, and the problems of side effect due to serum addition can be solved, risk due to exogenous pollution is reduced, stress reaction of animal is reduced, and subsequent processing is easy and simple.

The present invention relates to the field of biological products, and in particular relates to a vaccine freeze-drying protective agent containing no gelatin and human albumin. The vaccine freeze-drying protective agent comprises 1.5%-10% of sucrose, 1.5%-3.5% of dextran, 1%-2% of sorbitol, 0.8%-1.2% of sodium glutamate and 0.2% to 1% of L-arginine in a vaccine semi-finished product, a matrix liquid for preparation of the vaccine freeze-drying protective agent is 199 culture medium or PBS buffer solution or water for injection, the vaccine freeze-drying protective agent contains no gelatin and human albumin, and the vaccine semi-finished product is a liquid vaccine before freeze-drying. The present invention also provides the use of the vaccine freeze-drying protective agent. When the vaccine freeze-drying protective agent is used for the preparation of a freeze-dried vaccine, the vaccine freeze-drying protective agent can improve the vaccine stability during freeze-drying and storage processes, greatly improves the freeze-dried vaccine safety for human, and reduces adverse effects of the vaccine.

The invention especially relates to a method for producing a live vaccine against pseudorabies in swine from a continuous cell line, belonging to the technical field of biological products for livestock. The continuous cell line used in the invention is Vero cells. The method comprises the following steps: passage and culture of cells for vaccine preparation; propagation of virus seeds of the cells; propagation of virus liquid used for vaccine preparation; and vaccine preparation, split charging and freeze-drying. Porcine pseudorabies viruses obtained by using the method re high in content and titer; and the eventually prepared vaccine has high stability and long shelf life.